Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. - Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; et al. (Blood, 2021)